List view / Grid view
14 September 2015 | By Victoria White
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...
The US Food and Drug Administration (FDA) has approved AbbVie’s Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa.
11 September 2015 | By Victoria White
Allergan has said that its partner, Perrigo, will begin shipments of the products to its retail and wholesale customers in the US in time for the 2016 cough and cold season...
11 September 2015 | By Victoria White
Biogen is assessing the potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other autoimmune indications...
11 September 2015 | By Victoria White
The facility will eventually double AstraZeneca’s biologics manufacturing capacity in the US to meet the needs of the Company’s maturing pipeline...
11 September 2015 | By Victoria White
Interim results from the independent AMBER study demonstrated a 98% SVR12 rate in patients who completed a 12- or 24-week treatment regimen...
10 September 2015 | By Victoria White
The Indian domestic pharma market is estimated to reach US$ 15 billion by the end of the 2015 financial year, says India Brand Equity Foundation (IBEF)...
10 September 2015 | By Victoria White
The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all 28 Member States of the European Union...
Thermo Fisher Scientific, the world leader in serving science, announced that it received the in vitro diagnostics device (IVDD) CE mark for its Thermo Scientific Prelude MD HPLC, Endura MD mass spectrometer and ClinQuan MD software.
10 September 2015 | By Shimadzu
‘lab4you’ program for young scientists / Laboratory space available for research / Brief abstract for application...
10 September 2015 | By Victoria White
Daratumumab is an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma...
10 September 2015 | By Victoria White
Ixazomib is the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma...
10 September 2015 | By Victoria White
In the Phase 3 study, Kanuma met the primary endpoint of alanine aminotransferase (ALT) normalisation compared with placebo as well as six secondary endpoints...
9 September 2015 | By Victoria White
The value of the global treatment market for allergic rhinitis will witness minimal growth from $7.2 billion in 2014 to $7.3 billion by 2024, says research and consulting firm GlobalData...
9 September 2015 | By Victoria White
Data demonstrated that in 60 patients who received AZD9291 once daily in the first-line setting, 72% were progression free at 12 months...
